Researchers Study Use Of Dasatinib For Patients With High-Risk Myelodysplastic Syndromes
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. The therapy may not be effective for all patients, but those with trisomy 8 chromosomal disorder have higher rates of stable disease and respond better to treatment with dasatinib, the study shows. Results of this study appeared in the March issue of Leukemia Research... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS
(H. Lee Moffitt Cancer Center & Research Institute) Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 21, 2013 Category: Global & Universal Source Type: news
Robin Roberts' return to work spotlights resuming a career after cancer
Six months after she went on leave to treat her myelodysplastic syndromes, Good Morning America anchor Robin Roberts returns (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - February 20, 2013 Category: Consumer Health News Source Type: news
The Use of Cytogenetic Microarrays in Myelodysplastic Syndrome Characterization
Various microarray platforms, including BAC, oligonucleotide, and SNP arrays, have been shown to provide clinically useful diagnostic and prognostic information for patients with myelodysplastic syndromes (MDS). Clinically useful arrays are designed with specific purposes in mind and with attention to genomic content and probe density. All array types have been shown to detect genomic copy gains and losses, with SNP arrays having the added advantage of detecting copy neutral loss of heterozygosity (CNLOH). The finding of CNLOH has led to the identification of certain disease genes implicated in the initiation or progr...
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news
Apogenix Receives FDA Orphan Drug Designation For Apocept(TM) To Treat Myelodysplastic Syndromes And Initiates Clinical Phase I Study
Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that its lead product, Apocept(TM) (APG101), has been granted orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of Myelodysplastic syndromes (MDS). MDS are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenias, especially anemia... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 12, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Horizon Scanning: FDA grants orphan drug status for ApoceptT to treat myelodysplastic syndrome
Source: BioSpace
Area: News
Apogenix GMbH, a clinical stage biopharmaceutical company, has announced that the FDA has granted orphan drug designation for ApoceptT for the treatment of myelodysplastic syndrome (MDS).
A clinical phase I open-label trial is being initiated with ApoceptT in patients with MDS. Recruitment for the study began in January 2013.
ApoceptT binds to the CD95 ligand (CD95L) and blocks the activation of the CD95 receptor. Excessive stimulation of the CD95 receptor on hematopoietic cells present in the bone marrow of MDS patients inhibits erythropoiesis. As a result, transfusion-d...
Source: NeLM - News - February 8, 2013 Category: Drugs & Pharmacology Source Type: news
Acceleron commences Phase II myelodysplastic syndromes study of ACE-536
Biopharmaceutical company Acceleron Pharma has commenced a Phase II study to evaluate the safety, tolerability and efficacy of ACE-536 in patients with low-risk or intermediate-1 risk myelodysplastic syndromes (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - January 30, 2013 Category: Pharmaceuticals Source Type: news
Alkylating agents for Hodgkin's lymphoma tied to secondary leukemia
NEW YORK (Reuters Health) - Reducing exposure to alkylating agents in Hodgkin's lymphoma is key to
reducing the risk of therapy-related acute myeloid leukemia or myelodysplastic syndrome (t-AML/MDS), reports a
group from Stanford University, California. (Source: Modern Medicine)
Source: Modern Medicine - January 10, 2013 Category: Journals (General) Source Type: news
Robin Roberts Ready To Return
<p><img style="float: left; margin: 3px; border: 0px none;" src="http://0.tqn.com/d/breastcancer/1/0/q/0/-/-/robin_roberts_sm.jpg" alt="Robin Roberts" width="140" height="209" />GMA news host <a href="http://clk.about.com/?zi=1/1hc&zu=http://breastcancer.about.com/b/2007/07/31/robin-roberts-diagnosed-with-breast-cancer.htm">Robin Roberts</a> is almost ready to go back on the air, after having a bone marrow transplant (BMT). Roberts developed myelodysplastic syndrome (MDS) after having chemotherapy for ...<p><a href="h...
Source: About.com Breast Cancer - January 7, 2013 Category: Cancer & Oncology Source Type: news
New Clinical Advisory: Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN 0901)
The National Institutes of Health’s National Heart, Lung, and Blood Institute has suspended enrollment for the clinical study BMT CTN 0901 conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) after preliminary data appeared to show benefit for one approach to the intensity of conditioning for allogeneic stem cell transplantations in patients eligible for the study. (Source: PubMed New and Noteworthy)
Source: PubMed New and Noteworthy - June 18, 2012 Category: Databases & Libraries Source Type: news
New Clinical Advisory: Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN 0901)
The National Institutes of Health's National Heart, Lung, and Blood Institute has suspended enrollment for the clinical study BMT CTN 0901 conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) after preliminary data appeared to show benefit for one approach to the intensity of conditioning for allogeneic stem cell transplantations in patients eligible for the study. (Source: PubMed New and Noteworthy)
Source: PubMed New and Noteworthy - June 18, 2012 Category: Databases & Libraries Source Type: news
Discovery of Genetic Mutations Better Diagnose Myelodysplastic Syndromes
Researchers at BWH have developed a means of improving prognosis methods for patients with myelodysplastic syndromes. (Source: BWH News)
Source: BWH News - June 30, 2011 Category: Hospital Management Source Type: news
NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
FORT WASHINGTON, Pa., December 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines relating to the use of erythropoietin-stimulating agents (ESAs), such as epoetin alfa and darbepoetin alfa.
ESAs are no longer recommended for the treatment of cancer-related anemia associated with solid tumors or hematologic malignancies other than myelodysplastic syndromes (MDS). ESA therapy is an option for patient... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 20, 2007 Category: Cancer & Oncology Source Type: news
NCCN Updates Myelodysplastic Syndromes (MDS) Guidelines
JENKINTOWN, Pa., February 26, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Myelodysplastic Syndromes (MDS) Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. These guidelines are updated continually and are based upon evaluation of scientific data integrated with expert judgment.
One o... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 26, 2007 Category: Cancer & Oncology Source Type: news
NCCN Announces Important Updates to Myelodysplastic Syndromes Guidelines
JENKINTOWN, Pa., February 23, 2006 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Myelodysplastic Syndromes (MDS) Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care companies and by Medicare as the basis for coverage policies. These guidelines are ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 23, 2006 Category: Cancer & Oncology Source Type: news
